therapeutic effect of citicoline in treating severe and remission stages of Parkinson disease

Severe damage to the right brain nerve and fluctuating drug efficacy.

It is a core drug for nerve repair commonly used in neurology intensive care and chronic disease management.

It has an irreplaceable auxiliary therapeutic significance for patients with severe Parkinson's disease.

core significance of citicoline for severely ill Parkinson's patients

Severe Parkinson's patients suffer from extensive degeneration of neurons in the substantia nigra, and long-term use of core medications leads to nerve exhaustion and severe lack of blood supply to the brain.

They are prone to problems such as continuous worsening of symptoms, end-of-dose failure, and collapse of the autonomic nervous system.

The core value of citicoline lies in:

Delay nerve necrosis and preserve remaining nerve functions:

Targeted repair of damaged nigral dopaminergic neurons to prevent further decline of brain nerves and avoid rapid deterioration of the condition to a state of bedridden and complete disability.

Stabilize main therapeutic effect and reduce damage caused by drug resistance:

Alleviate the neurotoxicity caused by long-term use of levodopa drugs, enhance the utilization rate of the drugs, improve the "terminal effect" and "switching phenomenon", and enable severely ill patients to maintain their basic living abilities.

Improve critical illness symptoms and enhance quality of life:

Quickly alleviate the fatal discomforts during the critical stage, such as stiff body, inability to move, dizziness, blurred consciousness, palpitations and suffocation, night awakenings, and profuse sweating.

Restore brain circulation and reduce risk of complications:

Improve the ischemic and hypoxic state of the brain, reduce the probability of Parkinson's disease combined with cerebral infarction, cognitive impairment, and depression breakdown, and stabilize the body's basic condition.

Relieves brain fatigue, suitable for long-term severe condition treatment:

It has no hepatotoxicity or nephrotoxicity, and will not increase the metabolic burden on critically ill patients. It can be used as a basic neuroprotective medication for a long term.

Precision medication plan for Parkinson's disease stage III

(Acute phase + Chronic phase + Remission phase)

(1) Acute Phase / Crashing Phase

(Sudden severe symptoms, inability to take care of oneself, extreme discomfort)

Core objective: Provide rapid first aid, alleviate severe discomfort, stabilize vital signs, and survive the crisis.

Usage and Dosage: Prefer intravenous infusion; strictly prohibit oral administration.

Administration method: Intravenous infusion, performed by a professional nurse from the hospital's neurology department.

Course of treatment: Use continuously for 2 to 3 days, with the maximum duration not exceeding 7 days.

Core requirement: Must be hospitalized for treatment.

Doctors will continuously monitor heart rate, blood pressure and neurological condition. Self-administered intravenous infusion is strictly prohibited at home.

Efficacy characteristics: The drug enters the bloodstream directly.

It begins to take effect within 1-2 hours, quickly alleviating acute symptoms such as stiffness, palpitations, sudden awakening, and confusion.

(2) Chronic Phase

(Stable condition, routine maintenance, recurring symptoms)

Core objective: To achieve long-term nerve repair, stabilize the drug effect, delay the progression of the disease, and maintain the ability to live normally.

Usage and Dosage: Oral tablets. Take as a regular part of your daily routine at home.

Dosage: 0.2g each time (1 regular tablet), twice a day

Dosage time: Take one pill after breakfast and another pill after dinner. Taking the pills after meals can reduce gastrointestinal irritation.

Key requirements: Do not stop or increase the dosage without permission.

Please take the medicine consistently for a long term.

It should be combined with core drugs such as cabergoline, Sinemet, and Senfuro.

Efficacy characteristics: Mild and long-lasting effect.

Within 1-2 weeks, one can gradually experience stabilization of the nerves and a reduction in the fluctuation of the drug's efficacy.

(3) Recovery Period

(Symptoms are mild, the condition is stable, and there is no obvious discomfort)

Core objective: To consolidate the repair effect, prevent the recurrence of the disease, and protect the remaining neural functions.

Usage and dosage: Oral maintenance dose, for long-term stabilization

Dosage: 0.2g each time, 1-2 times a day (can be reduced to 1 time per day as per doctor's advice)

Dosage time: Take it after breakfast.

Key requirement: Do not completely discontinue the medication.

Avoid interruption of neuroprotective effects, which could lead to recurrence of symptoms. Regular follow-up visits are necessary to adjust the dosage.

Important Notes on Core Medications

This product is a neuroprotective auxiliary medicine.

It must not be used as a substitute for the core anti-Parkinson's drugs such as Carbidopa, Sinemet, and Senfuro.

During the acute phase, only intravenous infusion is allowed.

In the chronic phase and remission period, it must be switched to oral administration.

Long-term intravenous infusion is prohibited.

It is strictly prohibited to increase the dosage without permission.

Taking excessive amounts can lead to insomnia, irritability, elevated blood pressure and increase the burden on the body.

If you experience mild nausea or stomach discomfort during the oral administration, there is no need to stop taking the medicine.

Taking it after meals can help relieve the symptoms on its own.

Long-term use does not require frequent checks of liver and kidney functions. It is safe and suitable for the long-term management of severe Parkinson's disease.

If symptoms worsen or persist without relief during medication, seek medical attention immediately to adjust the treatment plan.

Core reminders for critically ill patients:

Citicoline is the "neuroprotective umbrella" for severe Parkinson's disease.

During the acute stage, it can be relieved through intravenous infusion for emergency treatment.

In the chronic stage, it can be protected by oral administration over a long period.

Adhering to the doctor's advice for medication throughout the process can effectively delay the progression of the disease, reduce the occurrence of breakdown episodes, and safeguard the dignity of life.

Clinical application precedents of Parkinson's disease

(Authoritative clinical evidence)

Citicoline has a large number of mature clinical precedents for the treatment of Parkinson's disease.

It is a routine auxiliary medication in neurology and Parkinson's disease clinics both at home and abroad.

It is not a niche medication. Its application scenarios cover the entire course of the disease from mild to severe.

Especially for patients with severe conditions, long disease duration, and combined neurological damage, the application rate is extremely high.

1. Clinical routine application situation

In all hospitals' neurology departments, cytidine diphosphate choline has been included in the standard adjunctive treatment plan for Parkinson's disease.

It is routinely prescribed for patients with black matter neuron damage, insufficient cerebral blood supply, fluctuating drug efficacy, combined cognitive impairment, and autonomic nerve disorders.

For patients with severe Parkinson's disease, as well as those with acute conditions / post-surgery / cerebral infarction accompanied by Parkinson's symptoms, the preferred clinical approach is to administer intravenous choline betaine to rapidly alleviate the emergency symptoms.

Subsequently, it is switched to oral administration for long-term maintenance. This is a commonly used emergency treatment combined with chronic disease management plan in clinical practice.

For patients with chronic diseases who have been taking levodopa, Sinemet and Senfuro for a long time, cytidine diphosphate choline is commonly used in combination for clinical purposes.

It is used to alleviate the neurotoxicity of the drugs, improve the "off" symptoms, and delay the progression of the disease. There are a large number of long-term follow-up clinical cases to support this.

2. Authority Application Basis

This product has been included in the relevant supplementary medication list for clinical diagnosis and treatment of Parkinson's disease.

It has clear clinical application recommendations for central nervous system degenerative diseases and Parkinson's syndrome related to cerebral ischemia and hypoxia.

Its safety and efficacy have been verified through long-term clinical trials.